The TMPRSS 2 : ERG Rearrangement , ERG Expression , and Prostate Cancer Outcomes : A Cohort Study and Meta-analysis
暂无分享,去创建一个
Jennifer R. Rider | M. Loda | P. Kantoff | M. Stampfer | E. Giovannucci | E. Ding | H. Sesso | A. Ligon | M. Sanda | M. Fiorentino | K. Penney | N. Martin | E. Stack | R. Lis | L. Mucci | C. Sweeney | A. Pettersson | R. E. Graff | R. Flavin | Lauren M. Kunz | C. Suppan | Michael J. Pitt | Scott R. Bauer | R. Graff
[1] I. Tannock,et al. Phase II study of cytarabine in men with docetaxel‐refractory, castration‐resistant prostate cancer with evaluation of TMPRSS2‐ERG and SPINK1 as serum biomarkers , 2012, BJU international.
[2] B. Donnelly,et al. ERG protein expression reflects hormonal treatment response and is associated with Gleason score and prostate cancer specific mortality. , 2012, European journal of cancer.
[3] R. Lothe,et al. FLI1 is a novel ETS transcription factor involved in gene fusions in prostate cancer , 2012, Genes, chromosomes & cancer.
[4] G. Jenster,et al. ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer , 2012, Modern Pathology.
[5] L. Tanoue. Cancer Statistics, 2011: The Impact of Eliminating Socioeconomic and Racial Disparities on Premature Cancer Deaths , 2012 .
[6] A. Partin,et al. Increased gene copy number of ERG on chromosome 21 but not TMPRSS2–ERG fusion predicts outcome in prostatic adenocarcinomas , 2011, Modern Pathology.
[7] Alvaro A. Martinez,et al. TMPRSS2/ERG fusion gene expression alters chemo‐ and radio‐responsiveness in cell culture models of androgen independent prostate cancer , 2011, The Prostate.
[8] S. Varambally,et al. TMPRSS2-ERG-mediated feed-forward regulation of wild-type ERG in human prostate cancers. , 2011, Cancer research.
[9] Nallasivam Palanisamy,et al. Urine TMPRSS2:ERG Fusion Transcript Stratifies Prostate Cancer Risk in Men with Elevated Serum PSA , 2011, Science Translational Medicine.
[10] J. Trapman,et al. Antibody EPR3864 is specific for ERG genomic fusions in prostate cancer: implications for pathological practice , 2011, Modern Pathology.
[11] E. Antonarakis,et al. Long‐term overall survival and metastasis‐free survival for men with prostate‐specific antigen‐recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database , 2011, BJU international.
[12] R. Henrique,et al. Relative 8q gain predicts disease‐specific survival irrespective of the TMPRSS2‐ERG fusion status in diagnostic biopsies of prostate cancer , 2011, Genes, chromosomes & cancer.
[13] H. Schlüter,et al. ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy , 2011, Clinical Cancer Research.
[14] J. Hicks,et al. Immunohistochemistry for ERG Expression as a Surrogate for TMPRSS2-ERG Fusion Detection in Prostatic Adenocarcinomas , 2011, The American journal of surgical pathology.
[15] Hiroyuki Takahashi,et al. Immunohistochemical ETS‐related gene detection in a Japanese prostate cancer cohort: Diagnostic use in Japanese prostate cancer patients , 2011, Pathology international.
[16] M. Rubin,et al. Relevance of cohort design for studying the frequency of the ERG rearrangement in prostate cancer , 2011, Histopathology.
[17] Wei Yan,et al. Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. , 2011, Cancer cell.
[18] M. Rubin,et al. TMPRSS2–ERG gene fusion prevalence and class are significantly different in prostate cancer of caucasian, african‐american and japanese patients , 2011, The Prostate.
[19] J. Squire,et al. Detection of ERG gene rearrangements and PTEN deletions in unsuspected prostate cancer of the transition zone , 2011, Cancer biology & therapy.
[20] O. Kallioniemi,et al. Arachidonic acid pathway members PLA2G7, HPGD, EPHX2, and CYP4F8 identified as putative novel therapeutic targets in prostate cancer. , 2011, The American journal of pathology.
[21] M. Rubin,et al. Single focus prostate cancer: pathological features and ERG fusion status. , 2011, The Journal of urology.
[22] M. Rubin,et al. Testing mutual exclusivity of ETS rearranged prostate cancer , 2010, Laboratory Investigation.
[23] B. Czerniak,et al. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. , 2011, Human pathology.
[24] K. Moon,et al. TMPRSS2-ERG gene fusion and clinicopathologic characteristics of Korean prostate cancer patients. , 2010, Urology.
[25] Y. Miyagi,et al. ETS family-associated gene fusions in Japanese prostate cancer: analysis of 194 radical prostatectomy samples , 2010, Modern Pathology.
[26] Xin Gao,et al. Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the early diagnosis of prostate cancer: a pilot study. , 2010, The Journal of molecular diagnostics : JMD.
[27] F. Deng,et al. Detection of TMPRSS2 Gene Deletions and Translocations in Carcinoma, Intraepithelial Neoplasia, and Normal Epithelium of the Prostate by Direct Fluorescence In Situ Hybridization , 2010, Diagnostic molecular pathology : the American journal of surgical pathology, part B.
[28] M. Rubin,et al. ERG rearrangement is present in a subset of transition zone prostatic tumors , 2010, Modern Pathology.
[29] S. Varambally,et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. , 2010, Neoplasia.
[30] K. Trpkov,et al. TMPRSS2-ERG gene fusion in transition zone prostate cancer , 2010, Modern Pathology.
[31] D. Berney,et al. Distinct genomic alterations in prostate cancers in Chinese and Western populations suggest alternative pathways of prostate carcinogenesis. , 2010, Cancer research.
[32] S-H Tan,et al. ERG oncoprotein expression in prostate cancer: clonal progression of ERG-positive tumor cells and potential for ERG-based stratification , 2010, Prostate Cancer and Prostatic Diseases.
[33] Tapio Visakorpi,et al. Association of SPINK1 Expression and TMPRSS2:ERG Fusion with Prognosis in Endocrine-Treated Prostate Cancer , 2010, Clinical Cancer Research.
[34] J. López-Guerrero,et al. Clinical implications of TMPRSS2-ERG gene fusion expression in patients with prostate cancer treated with radical prostatectomy. , 2010, The Journal of urology.
[35] L. Collette,et al. Expression of the androgen-regulated fusion gene TMPRSS2-ERG does not predict response to endocrine treatment in hormone-naïve, node-positive prostate cancer. , 2010, European urology.
[36] R. Shah,et al. ETS Gene Aberrations in Atypical Cribriform Lesions of the Prostate: Implications for the Distinction Between Intraductal Carcinoma of the Prostate and Cribriform High-grade Prostatic Intraepithelial Neoplasia , 2010, The American journal of surgical pathology.
[37] Mehmet Toner,et al. Isolation and Characterization of Circulating Tumor Cells from Patients with Localized and Metastatic Prostate Cancer , 2010, Science Translational Medicine.
[38] M. Rubin,et al. Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort , 2009, Modern Pathology.
[39] M. Gerstein,et al. Molecular sampling of prostate cancer: a dilemma for predicting disease progression , 2010, BMC Medical Genomics.
[40] J. Brooks,et al. Prognostic significance of prostate cancer originating from the transition zone. , 2009, Urologic oncology.
[41] W. Isaacs,et al. TMPRSS2–ERG gene fusion status in minute (minimal) prostatic adenocarcinoma , 2009, Modern Pathology.
[42] A. Haese*,et al. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis , 2009, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[43] M. Rubin,et al. ETS gene fusions in prostate cancer: from discovery to daily clinical practice. , 2009, European urology.
[44] C. Cooper,et al. ETS gene fusions in prostate cancer , 2009, Nature Reviews Urology.
[45] Jing Ma,et al. Gleason score and lethal prostate cancer: does 3 + 4 = 4 + 3? , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[46] Arul M Chinnaiyan,et al. Prevalence of TMPRSS2-ERG Fusion Prostate Cancer among Men Undergoing Prostate Biopsy in the United States , 2009, Clinical Cancer Research.
[47] B. Czerniak,et al. Prostate cancer of transition zone origin lacks TMPRSS2–ERG gene fusion , 2009, Modern Pathology.
[48] E. Baldi,et al. Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: Preliminary results , 2009, Journal of endocrinological investigation.
[49] R. Shah,et al. The Discovery of Common Recurrent Transmembrane Protease Serine 2 (TMPRSS2)-Erythroblastosis Virus E26 Transforming Sequence (ETS) Gene Fusions in Prostate Cancer: Significance and Clinical Implications , 2009, Advances in anatomic pathology.
[50] E. Platz,et al. TMPRSS2-ERG gene fusions are infrequent in prostatic ductal adenocarcinomas , 2009, Modern Pathology.
[51] G. Jenster,et al. Overexpression of Prostate-Specific TMPRSS2(exon 0)-ERG Fusion Transcripts Corresponds with Favorable Prognosis of Prostate Cancer , 2009, Clinical Cancer Research.
[52] W. Gerald,et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. , 2009, Cancer research.
[53] C. LaFargue,et al. TMPRSS2-ERG fusion is frequently observed in gleason pattern 3 prostate cancer in a Canadian cohort , 2009, Cancer biology & therapy.
[54] M. Rubin,et al. Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer. , 2009, Cancer research.
[55] J. Manson,et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. , 2009, JAMA.
[56] O. Ludkovski,et al. Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome , 2008, Modern Pathology.
[57] Ziding Feng,et al. Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome. , 2008, Clinical chemistry.
[58] S. Fröhling,et al. Chromosomal abnormalities in cancer. , 2008, The New England journal of medicine.
[59] M. Gleave,et al. Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer , 2008, BMC Cancer.
[60] T. Tammela,et al. TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis , 2008, Clinical Cancer Research.
[61] J. Amiel,et al. Detection of the TMPRSS2-ETS fusion gene in prostate carcinomas: retrospective analysis of 55 formalin-fixed and paraffin-embedded samples with clinical data. , 2008, Cancer genetics and cytogenetics.
[62] S. Srivastava,et al. Mapping of TMPRSS2–ERG fusions in the context of multi-focal prostate cancer , 2008, Modern Pathology.
[63] J Cuzick,et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer , 2008, Oncogene.
[64] J. Trachtenberg,et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer , 2007, British Journal of Cancer.
[65] R. Shah,et al. Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. , 2007, Cancer research.
[66] Yao-Tseng Chen,et al. Gene fusions between TMPRSS2 and ETS family genes in prostate cancer: frequency and transcript variant analysis by RT-PCR and FISH on paraffin-embedded tissues , 2007, Modern Pathology.
[67] Debashis Ghosh,et al. Comprehensive assessment of TMPRSS2 and ETS family gene aberrations in clinically localized prostate cancer , 2007, Modern Pathology.
[68] J. Damber,et al. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. , 2007, Oncology reports.
[69] J. Brooks,et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis , 2007, Modern Pathology.
[70] S. Leung,et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers , 2007, Journal of Clinical Pathology.
[71] P. Kantoff,et al. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort , 2007, Oncogene.
[72] G. Jenster,et al. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. , 2006, Cancer research.
[73] Lei Wang,et al. Noninvasive detection of TMPRSS2:ERG fusion transcripts in the urine of men with prostate cancer. , 2006, Neoplasia.
[74] J. Tchinda,et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.
[75] J. Tchinda,et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.
[76] A. Seth,et al. ETS transcription factors and their emerging roles in human cancer. , 2005, European journal of cancer.
[77] Alan W Partin,et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. , 2005, JAMA.
[78] L. Hood,et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. , 1999, Cancer research.
[79] P. Scardino,et al. Anatomy of the prostate and distribution of early prostate cancer. , 1995, Seminars in surgical oncology.
[80] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[81] C. Hennekens,et al. A randomized trial of aspirin and beta-carotene among U.S. physicians. , 1985, Preventive medicine.